Esketamine for the Treatment of Rett Syndrome

This single-group interventional study will evaluate the efficacy and safety of intravenous esketamine (0.25 mg/kg) given weekly for five weeks in children aged 5–10 years with classic Rett syndrome caused by MECP2 mutation.

Participants receive five once-weekly 40-minute IV infusions (esketamine diluted in 20 ml saline). Outcomes include disease severity measures and safety assessments; stable seizure status is required at enrolment.